14
November

08:00 AM EST

Drug Discovery Biology

Strategy Meeting East Coast USA 2022

Understanding Complex Structure, Properties and Dynamics of Biological Phenomena in Drug Discovery: Emerging Tools and Next Generation Drug Target Characterization, Validation and Safety Profiling

Le Meridien Cambridge Boston

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Biology Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Biology professionals from across the East Coast, in Boston MA, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our 2022 Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Drug Discovery Biology strategy meeting.

Henry Lu

VP & Head of Discovery Biology WuXi AppTec

Letian Kuai, Ph.D

Executive Director, DEL Technology and Strategy Chief Scientific Officer, Crelux WuXi AppTec

Andreas Schoops

Head of Medicinal Chemistry WuXi AppTec

Dominic Hussey

Territorial Head-EMEA Sales Bit.Bio

Scott Heyward

Leading Product Development and Scientific Engagement BioIVT Inc

Terri Almos

Executive Director, Emerging Science & Innovation Inflammation & Immunology Pfizer

Karim Azer

Vice President, Head of Platform & Discovery Axcella

Dr. Karim Azer is the Vice President, Head of the Systems Biology Platform & Discovery at Axcella Therapeutics. He leads the data and discovery sciences organization at Axcella, bringing together innovations in data sciences and discovery sciences to advance novel pipeline opportunities through the application of systems biology, design of novel endogenous metabolic modulator combinations for new indications, and the translation of these combinations into the clinic. Prior to Axcella, Karim led quantitative sciences efforts at the Bill & Melinda Gates Medical Research Institute where His work was focused on leveraging the spectrum of systems biology, including computational biology, systems pharmacology, modeling and data science, to address research and development needs of the institute, in the areas of tuberculosis, malaria, diarrheal and enteric diseases, and maternal neonatal health. Prior to that, Karim was at Merck and Sanofi, where he led and applied systems biology and pharmacology, and data science efforts towards advancing drug discovery and development programs across a wide array of therapeutics areas. Karim received his PhD in Applied Mathematics from the Courant Institute of Mathematical Sciences at NYU, and holds an M.S. in Applied Mathematics from Courant Institute at NYU, and B.S. degrees in Mathematics and Computer Science from Rutgers University. He has worked in the pharmaceutical industry since 1997, employing a wide variety of systems biology approaches to address drug discovery and development initiatives in R&D.

Carla Bauer

Associate Director, Strategic Transactions, Business Development & Licensing Novartis

Govinda Bhisetti

Vice President and Head of Computational Chemistry Cellarity

Matthew Calabrese

Senior Director and Head of Structural and Molecular Sciences Pfizer

Prasoon Chaturvedi

Vice President, Head of DMPK C4 Therapeutics, Inc.

Brent Cezairliyan

Vice President, Biology Octagon Therapeutics

Rob Foti

Senior Director, Preclinical Development (ADME & Discovery Toxicology) MERCK

Vibha Jawa

Executive Director, Nonclinical Disposition and Bioanalysis Bristol Myers Squibb

Matthew Lech

Principal Research Scientist Pfizer

Jing Li

Executive Director Biology PTC Therapeutics, Inc.

Jing Li, Ph.D – Jing joined<a href="https://www.ptcbio.com/"> PTC Therapeutics</a> in January 2020 as Executive Director, Biology, with the goal of advancing novel small molecules, including RNA splicing modulators, for the treatment of inflammatory diseases and cancer. Prior to joining PTC, he was the Chief Scientific Officer at Eternity Bioscience, Inc. Prior to that he worked at Merck Research Laboratories for fifteen years with various roles and increased responsibilities, including Director of Biology Discovery, Director of Pharmacology. Jing received his Ph.D. in Microbiology and Immunology from Medical College of Pennsylvania, B.S. degree in Biochemistry from University of Nevada and M.B. in Medicine from Shanghai Medical University. Jing discovered novel tumor suppressor gene, PTEN, while he was post-doctoral fellow at Columbia University. Jing co-authored over fifty scientific and patent publications, including in the journals of Science, Nature Genetics.

Diane Joseph-McCarthy

Executive Director, Bioengineering Technology & Entrepreneurship Center Boston University

Li Peng

Chief Scientific Officer Palleon Pharmaceuticals

Nisha Perez

Senior Director, Head of DMPK ROME Therapeutics

John Reilly

Chief Scientific Officer Nereid Therapeutics

Cara Williams

Vice President Head of Preclinical Biology, Inflammation & Immunology Research Unit Pfizer

Dr Cara Williams earned her PhD (Immunopharmacology), from Liverpool University, England UK. During her PhD studies she completed an internship at Boots/BASF/Knoll laboratories in Nottingham England where she found her passion for drug discovery and drug development. Following her PhD she completed a short postdoc at Liverpool University in the Department of Bioengineering before moving to the USA to embrace her love of mast cells; that annoying culprit involved in such things as anaphylaxis, allergy, asthma, worm and tick expulsion, itch, and the list continues to grow! She completed her postdoctoral studies on mast cell biology at Harvard University- Beth Israel Deaconess Medical Center. She then moved to Stanford University, Palo Alto CA to continue her research into mast cell function in health and disease. Nevertheless, as a devoted drug discovery pharmacologist with an interest in turning basic research into new therapeutic breakthroughs for patients, Cara moved into the preclinical drug discovery world of biotech/pharma joining Genetics Institute/AHP, Wyeth, Pfizer and later to Boehringer Ingelheim in Germany. She returned to Pfizer USA in 2019 and now leads the Preclinical Biology research line within the Inflammation & Immunology Research Unit at the Cambridge MA site within Pfizer PRDM.

First name	Last name	Job title	Company name	Photo URL	Bio Position
Henry	Lu	VP & Head of Discovery Biology	WuXi AppTec	https://proventainternational.com/wp-content/uploads/2021/04/Henry-Lu-New.jpg
Letian	Kuai, Ph.D	Executive Director, DEL Technology and Strategy Chief Scientific Officer, Crelux	WuXi AppTec	https://proventainternational.com/wp-content/uploads/2021/04/Letian-Kuai-e1618391978804.jpg
Andreas	Schoops	Head of Medicinal Chemistry	WuXi AppTec	https://proventainternational.com/wp-content/uploads/2022/10/Andreas-Schoop.jpg
Dominic	Hussey	Territorial Head-EMEA Sales	Bit.Bio	https://proventainternational.com/wp-content/uploads/2022/10/Dominic-Hussey.jpg
Scott	Heyward	Leading Product Development and Scientific Engagement	BioIVT Inc	https://proventainternational.com/wp-content/uploads/2022/11/Scott-Heyward.jpg
Terri	Almos	Executive Director, Emerging Science & Innovation Inflammation & Immunology	Pfizer	https://proventainternational.com/wp-content/uploads/2022/09/Terri-Almos.jpg	Terri Almos is an Executive Director in Pfizer’s External Scientific & Innovation team located in Cambridge, MA. Dr. Almos has more than 20 years experience in drug discovery in inflammatory, oncology, and CNS disease areas. Prior to joining Pfizer, Dr. Almos was a Senior Director in GSK’s Business Development search and evaluation team, and also managed the GSK/Avalon Ventures ’Build-to-Buy’ research incubator in San Diego. Dr. Almos received her BS in Microbiology from the Pennsylvania State University, a PhD in Immunology from Johns Hopkins University, and completed a Postdoctoral Fellowship at Johns Hopkins in Developmental Neuroscience.
Karim	Azer	Vice President, Head of Platform & Discovery	Axcella	https://proventainternational.com/wp-content/uploads/2022/10/Karim-Azer-1.jpg	Dr. Karim Azer is the Vice President, Head of the Systems Biology Platform & Discovery at Axcella Therapeutics. He leads the data and discovery sciences organization at Axcella, bringing together innovations in data sciences and discovery sciences to advance novel pipeline opportunities through the application of systems biology, design of novel endogenous metabolic modulator combinations for new indications, and the translation of these combinations into the clinic. Prior to Axcella, Karim led quantitative sciences efforts at the Bill & Melinda Gates Medical Research Institute where His work was focused on leveraging the spectrum of systems biology, including computational biology, systems pharmacology, modeling and data science, to address research and development needs of the institute, in the areas of tuberculosis, malaria, diarrheal and enteric diseases, and maternal neonatal health. Prior to that, Karim was at Merck and Sanofi, where he led and applied systems biology and pharmacology, and data science efforts towards advancing drug discovery and development programs across a wide array of therapeutics areas. Karim received his PhD in Applied Mathematics from the Courant Institute of Mathematical Sciences at NYU, and holds an M.S. in Applied Mathematics from Courant Institute at NYU, and B.S. degrees in Mathematics and Computer Science from Rutgers University. He has worked in the pharmaceutical industry since 1997, employing a wide variety of systems biology approaches to address drug discovery and development initiatives in R&D.
Carla	Bauer	Associate Director, Strategic Transactions, Business Development & Licensing	Novartis	https://proventainternational.com/wp-content/uploads/2022/09/Carla-Bauer.jpg	Dr. Carla Bauer is a strategic leader who possesses a breadth of experience in the biopharmaceutical industry. Carla has worked across multiple modalities and therapeutic areas, including respiratory, oncology, and immunology. Her diverse experiences across various types of roles have spanned leading teams of scientists working at the bench on early drug discovery programs, to building complex collaborations, to her most recent foray into Business Development and Licensing. Carla has acted as an Alliance Manager, has directed focused Search and Evaluation efforts, and has executed complex negotiations for various types of strategic transactions for the Novartis Institutes of BioMedical Research.
Govinda	Bhisetti	Vice President and Head of Computational Chemistry	Cellarity	https://proventainternational.com/wp-content/uploads/2020/08/Govinda-Bhisetti-1.jpg	Govinda Bhisetti got his Ph.D. from the Indian I at Vertex Pharmaceuticals Inc. in 1990 and worked in the Computational Sciences department for 22+ yenstitute of Science, Bangalore, in 1986. He joined the Scripps Research Institute in La Jolla, CA, as a postdoctoral fellow in 1987. His work at Scripps involved the use of Cray XMP supercomputers to simulate protein-ligand interactions and design novel inhibitors. From there, he went to workars, where he led molecular modeling and drug design efforts on several drug discovery projects. His research at Vertex led to the discovery of three FDA- approved drugs: two AIDS drugs, Agenerase (amprenavir) and Lexiva (fosamprenavir), and one hepatitis C drug, Incivek (Telaprevir). He is a co-inventor of these drugs and has been named an inventor on 26 patents. He published 72 research papers, including review articles and book chapters.
Matthew	Calabrese	Senior Director and Head of Structural and Molecular Sciences	Pfizer	https://proventainternational.com/wp-content/uploads/2022/07/Matthew-Calabrese.jpg	Matt Calabrese obtained his PhD in Molecular Biophysics and Biochemistry from Yale University where he studied protein folding in the lab of Dr. Andrew Miranker. He then moved on to a postdoctoral fellowship with Dr. Brenda Schulman at St. Jude Children’s Research Hospital where he studied the structure and function of the ubiquitin proteasome system, with a focus on cullin-RING E3 ligases. In 2011, Matt joined Pfizer as a Senior Scientist in structural biology, and at present, he is Senior Director and Head of the Structural and Molecular Sciences department.
Prasoon	Chaturvedi	Vice President, Head of DMPK	C4 Therapeutics, Inc.	https://proventainternational.com/wp-content/uploads/2022/06/Prasoon-Chaturvedi.jpg	Prasoon Chaturvedi, Ph.D., currently leads the DMPK efforts in the protein degrader space as Vice President, DMPK, at C4 Therapeutics in Watertown, MA. Over the last two decades, Prasoon has worked with numerous cutting-edge technologies to drive drug development endeavors in multiple therapeutic areas including infectious disease, oncology, hematology, cardiovascular, inflammation and rare diseases leading to multiple successful IND, CTA, and NDA filings and has made key DMPK contributions for several marketed drugs including NUZYRA® and ONPATTRO®. Prasoon holds a Ph.D. from IIT, Roorkee (India), and did his post-doctoral training at E.K. Shriver Center of Harvard Medical School, MA.
Brent	Cezairliyan	Vice President, Biology	Octagon Therapeutics	https://proventainternational.com/wp-content/uploads/2022/03/Brent-Cezairliyan.jpg	Brent Cezairliyan, Ph.D. received his doctoral training in biochemistry and biophysics at MIT, studying the regulation of transmembrane signaling in the unfolded protein response. His postdoctoral work at Massachusetts General Hospital resulted in the development of quantitative models of signaling and exoproduct production of microbial pathogens based on their metabolism and growth in complex substrates. As Vice President of Biology at Octagon Therapeutics, Dr. Cezairliyan has led the autoimmune disease metabolism research program to develop novel targeted small molecule therapeutics that suppress autoimmune responses in pathogenic lymphocytes.
Rob	Foti	Senior Director, Preclinical Development (ADME & Discovery Toxicology)	MERCK	https://proventainternational.com/wp-content/uploads/2022/10/Rob-Foti.jpg	Dr. Foti is a Senior Director at Merck where he leads drug disposition across multiple therapeutic areas. Prior to joining Merck, Rob held positions at Amgen, Inc., supporting multi-modality drug discovery and development efforts, and at Pfizer, contributing to high-throughput ADME assays. Collectively, Rob has over 20 years of driving innovative research in the pharmaceutical industry. Externally, Rob is an Associate Editor for Drug Metabolism and Disposition, serves on the Editorial Board for Xenobiotica and is a past Chair for the Drug Metabolism and Disposition Division of the American Society for Pharmacology and Experimental Therapeutics.
Vibha	Jawa	Executive Director, Nonclinical Disposition and Bioanalysis	Bristol Myers Squibb	https://proventainternational.com/wp-content/uploads/2021/02/Vibha-Jawa.jpeg	Vibha brings more than 20+ years of experience in supporting biologics, vaccine development, and gene therapy with contributions to multiple IND, BLA, and MAA filings. She is a recognized leader in the area of Bioanalysis and Immunogenicity with more than 50 peer-reviewed publications. In her current role as an Executive Director for Biotherapeutics Bioanalysis at Bristol Myers Squibb, Vibha is responsible for leading biotherapeutic and cell therapy bioanalytical (BA) functions. Her research interest has focused on streamlining preclinical immunogenicity assessments by using algorithms and in vitro human-derived assays and using those outputs to drive a risk-based clinical strategy. She is an active member of multiple industry groups like AAPS and the Industry Innovation and Quality (IQ) Consortium for Cell/Viral/Gene therapies.
Matthew	Lech	Principal Research Scientist	Pfizer	https://proventainternational.com/wp-content/uploads/2022/09/Matthew-Lech.jpg	Matt is a scientist at Pfizer in the Discovery Fibrosis Group within Inflammation and Immunology. His focus is on implementing complex model systems into the drug development process to better predict human responses and increase late-stage program success. Matt’s background in complex model systems started in graduate school with early development of complex microtissues for use in cell-to-cell communication and cellular mechanics. He looks forward to a lively discussion on the current and future use of complex model systems in the drug development pipeline.
Jing	Li	Executive Director Biology	PTC Therapeutics, Inc.	https://proventainternational.com/wp-content/uploads/2021/02/Jing-Li.jpg	Jing Li, Ph.D – Jing joined PTC Therapeutics in January 2020 as Executive Director, Biology, with the goal of advancing novel small molecules, including RNA splicing modulators, for the treatment of inflammatory diseases and cancer. Prior to joining PTC, he was the Chief Scientific Officer at Eternity Bioscience, Inc. Prior to that he worked at Merck Research Laboratories for fifteen years with various roles and increased responsibilities, including Director of Biology Discovery, Director of Pharmacology. Jing received his Ph.D. in Microbiology and Immunology from Medical College of Pennsylvania, B.S. degree in Biochemistry from University of Nevada and M.B. in Medicine from Shanghai Medical University. Jing discovered novel tumor suppressor gene, PTEN, while he was post-doctoral fellow at Columbia University. Jing co-authored over fifty scientific and patent publications, including in the journals of Science, Nature Genetics.
Diane	Joseph-McCarthy	Executive Director, Bioengineering Technology & Entrepreneurship Center	Boston University	https://proventainternational.com/wp-content/uploads/2022/07/Diane-Joseph-McCarthy.jpg	Diane Joseph-McCarthy is the Executive Director of the Bioengineering Technology & Entrepreneurship Center and Professor of the Practice in Biomedical Engineering at Boston University. Prior to that, she was a senior life science executive with over 20 years of drug discovery, development, and leadership experience. She was SVP of Discovery & Early Development at EnBiotix, a bioengineering company focused on respiratory and rare disease. She was an Associate Director at AstraZeneca, where she led a global team and task forces to transform Infection’s early portfolio. At Wyeth, she held positions of increasing responsibility. Diane received her PhD from MIT and was a postdoctoral fellow at Harvard University/Harvard Medical School.
Li	Peng	Chief Scientific Officer	Palleon Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2022/08/Li-Peng.jpg	Li Peng is Chief Scientific Officer of Palleon Pharmaceuticals, a leading biotechnology company developing drugs that target glycan-mediated immune regulation to treat cancer and inflammatory diseases. Li has led the invention of EAGLE, CONVERGENCE, and HYDRA platform technologies and overseen research and early development at Palleon. Prior to joining Palleon, Li had worked at Medimmune/AstraZeneca for ten years in roles of increasing responsibility. She has published ~30 scientific papers and is an inventor on ~30 patents and patent applications. Li earned a doctorate in biochemistry and molecular biology from the University of California, Davis.
Nisha	Perez	Senior Director, Head of DMPK	ROME Therapeutics	https://proventainternational.com/wp-content/uploads/2022/08/Heather-Carlson-1.jpg	Nisha Perez is the Senior Director and Head of DMPK at Rome Therapeutics in Cambridge, MA. Formerly, she worked at Blueprint Medicines as Director of DMPK and Clinical Pharmacology and before that, she spent 12 years at Ironwood Pharmaceuticals. She has worked across multiple therapeutic areas including cancer, immuno-oncology, rare diseases, fibrosis, inflammation, women’s health, and GI. She has contributed to multiple program strategies and regulatory filings. She has had the honor of following several candidates into the clinic, through approval and post-marketing requirements. She holds 2 patents, one being an LCMS diagnostic biomarker method.
John	Reilly	Chief Scientific Officer	Nereid Therapeutics	https://proventainternational.com/wp-content/uploads/2022/10/John-Reilly.jpg
Cara	Williams	Vice President Head of Preclinical Biology, Inflammation & Immunology Research Unit	Pfizer	https://proventainternational.com/wp-content/uploads/2020/01/Cara-Williams.jpeg	Dr Cara Williams earned her PhD (Immunopharmacology), from Liverpool University, England UK. During her PhD studies she completed an internship at Boots/BASF/Knoll laboratories in Nottingham England where she found her passion for drug discovery and drug development. Following her PhD she completed a short postdoc at Liverpool University in the Department of Bioengineering before moving to the USA to embrace her love of mast cells; that annoying culprit involved in such things as anaphylaxis, allergy, asthma, worm and tick expulsion, itch, and the list continues to grow! She completed her postdoctoral studies on mast cell biology at Harvard University- Beth Israel Deaconess Medical Center. She then moved to Stanford University, Palo Alto CA to continue her research into mast cell function in health and disease. Nevertheless, as a devoted drug discovery pharmacologist with an interest in turning basic research into new therapeutic breakthroughs for patients, Cara moved into the preclinical drug discovery world of biotech/pharma joining Genetics Institute/AHP, Wyeth, Pfizer and later to Boehringer Ingelheim in Germany. She returned to Pfizer USA in 2019 and now leads the Preclinical Biology research line within the Inflammation & Immunology Research Unit at the Cambridge MA site within Pfizer PRDM.

Henry Lu, Letian Kuai, Ph.D, Andreas Schoops, Dominic Hussey, Scott Heyward, Terri Almos, Karim Azer, Carla Bauer, Govinda Bhisetti, Matthew Calabrese, Prasoon Chaturvedi, Brent Cezairliyan, Rob Foti, Vibha Jawa, Matthew Lech, Jing Li, Diane Joseph-McCarthy, Li Peng, Nisha Perez, John Reilly, Cara Williams

See the full agenda and facilitator line-up

Download the strategy meeting brochure for full details

DOWNLOAD THE BROCHURE

Who Should Attend the Event?

Chief Scientific Officer

Vice President, Head Research Pharmacokinetics

Global Head, Modeling and Simulation

Vice President of Biology

Head of Discovery Chemistry, Screening Biology & Operations

Head of Discovery Biology

Head of Structural Biology & Biophysics

Head of Target Science, Target & Translational Science

Head of Protein & Structural Sciences

Head of Pharmacology

Discovery DMPK & ADME

Drug Metabolism & Pharmacokinetics

See Which Topics Are Discussed at the Strategy Meeting

09:00 – 10:00

Roundtable Tracks

Optimizing The Target Identification and Validation Processes: Select Novel and Human Disease Translatable Targets Through Genetics, Cellular, Molecular, Omics, and Other Approaches

Biomolecular Condensates: Structural and Biophysical Approaches for Drug Discovery

PB/PK Toxicity Modeling: Lowering The Risk Of Drug Discovery Failure Due To Low Efficacy Rate And High Toxicity Rate

Strengths and Limitations of Animal Models in Drug Development

Big Data and AI: Integration and Harnessing the Full Potential of Massive Data Sets to use in small molecule Drug Discovery

Collaborative Approach of Industry and Academia for Accelerated Development and New Breakthroughs

11:10 – 12:10

Roundtable Tracks

Leveraging the Power of Multi-Omics in Drug Discovery: Maximizing the Potential in Target Identification and Safety Profiling WUXI APPTEC

The future of Protein Structure Prediction Algorithm: Advantages, Applications and Limitations in Drug Discovery WUXI APPTEC

Utilizing Specialized Non-Clinical Resources to Support Drug Development BIOIVT

Addressing the current challenges of in vitro cell models and their translation into the clinic BIT.BIO

In vitro bioassays and in vivo pharmacology to support RNA biology WUXI APPTEC

Why should you attend this meeting?

Understanding recent advances and alternatives for drug discovery stages discovery, development and preclinical stages that could lead to cost cutting, efficiency and early detection

Leveraging multi-omics analysis data, its advantages and limitations to further the possibilities for drug discovery applications

Exploring the discrepancy in drug metabolism between different genders and ethnic diversification that could lead to understanding the pharmacokinetics distinction between genders and ethnicity

Collaborative approaches and networking opportunities with different top-tier industry solution providers

Press play to hear what your colleagues had to say…

Become an official strategy meeting partner

Whatever your business needs, we can help. Get in touch for partnering opportunities

I’D LIKE TO PARTNER

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Boston

Medicinal Chemistry Strategy Meeting East Coast – Boston 2024

Drug Discovery Biology

Strategy Meeting East Coast USA 2022

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Le Meridien Cambridge Boston

Fresh Biology Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our 2022 Facilitators

Henry Lu

Letian Kuai, Ph.D

Andreas Schoops

Dominic Hussey

Scott Heyward

Terri Almos

Karim Azer

Carla Bauer

Govinda Bhisetti

Matthew Calabrese

Prasoon Chaturvedi

Brent Cezairliyan

Rob Foti

Vibha Jawa

Matthew Lech

Jing Li

Diane Joseph-McCarthy

Li Peng

Nisha Perez

John Reilly

Cara Williams

See the full agenda and facilitator line-up

Who Should Attend the Event?

Chief Scientific Officer

Vice President, Head Research Pharmacokinetics

Global Head, Modeling and Simulation

Vice President of Biology

Head of Discovery Chemistry, Screening Biology & Operations

Head of Discovery Biology

Head of Structural Biology & Biophysics

Head of Target Science, Target & Translational Science

Head of Protein & Structural Sciences

Head of Pharmacology

Discovery DMPK & ADME

Drug Metabolism & Pharmacokinetics

See Which Topics Are Discussed at the Strategy Meeting

REGISTRATION AND WELCOME

OPENING KEYNOTE PRESENTATIONADME Challenges and Strategies for Protein Degraders

Roundtable

Roundtable Tracks

Optimizing The Target Identification and Validation Processes: Select Novel and Human Disease Translatable Targets Through Genetics, Cellular, Molecular, Omics, and Other Approaches

Biomolecular Condensates: Structural and Biophysical Approaches for Drug Discovery

PB/PK Toxicity Modeling: Lowering The Risk Of Drug Discovery Failure Due To Low Efficacy Rate And High Toxicity Rate

Strengths and Limitations of Animal Models in Drug Development

Big Data and AI: Integration and Harnessing the Full Potential of Massive Data Sets to use in small molecule Drug Discovery

Collaborative Approach of Industry and Academia for Accelerated Development and New Breakthroughs

REFRESHMENT BREAK

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

Roundtable

Roundtable Tracks

Leveraging the Power of Multi-Omics in Drug Discovery: Maximizing the Potential in Target Identification and Safety Profiling WUXI APPTEC

The future of Protein Structure Prediction Algorithm: Advantages, Applications and Limitations in Drug Discovery WUXI APPTEC

Utilizing Specialized Non-Clinical Resources to Support Drug Development BIOIVT

Addressing the current challenges of in vitro cell models and their translation into the clinic BIT.BIO

In vitro bioassays and in vivo pharmacology to support RNA biology WUXI APPTEC

NETWORKING LUNCH

Why should you attend this meeting?

Our 2022 Lead Sponsor

Le Meridien Cambridge Boston

OPENING KEYNOTE PRESENTATION
ADME Challenges and Strategies for Protein Degraders